Cargando…

Recent Advances in Understanding and Managing Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle leading to abnormal structure or function in the absence of coronary artery disease, hypertension, or valvular or congenital heart disease. Currently, cardiomyopathy is the leading diagnosis of heart transplant patients worldwide. Incorporation of next...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez, Paulino, Tang, WH Wilson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590086/
https://www.ncbi.nlm.nih.gov/pubmed/28928965
http://dx.doi.org/10.12688/f1000research.11669.1
_version_ 1783262466103312384
author Alvarez, Paulino
Tang, WH Wilson
author_facet Alvarez, Paulino
Tang, WH Wilson
author_sort Alvarez, Paulino
collection PubMed
description Cardiomyopathy is a disease of the heart muscle leading to abnormal structure or function in the absence of coronary artery disease, hypertension, or valvular or congenital heart disease. Currently, cardiomyopathy is the leading diagnosis of heart transplant patients worldwide. Incorporation of next-generation sequencing strategies will likely revolutionize genetic testing in cardiomyopathy. The use of patient-specific pluripotent stem cell-derived cardiomyocytes for disease modeling and therapeutic testing has opened a new avenue for precision medicine in cardiomyopathy. Stem cell therapy, gene therapy, interfering RNA, and small molecules are actively being evaluated in clinical trials.
format Online
Article
Text
id pubmed-5590086
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher F1000Research
record_format MEDLINE/PubMed
spelling pubmed-55900862017-09-18 Recent Advances in Understanding and Managing Cardiomyopathy Alvarez, Paulino Tang, WH Wilson F1000Res Review Cardiomyopathy is a disease of the heart muscle leading to abnormal structure or function in the absence of coronary artery disease, hypertension, or valvular or congenital heart disease. Currently, cardiomyopathy is the leading diagnosis of heart transplant patients worldwide. Incorporation of next-generation sequencing strategies will likely revolutionize genetic testing in cardiomyopathy. The use of patient-specific pluripotent stem cell-derived cardiomyocytes for disease modeling and therapeutic testing has opened a new avenue for precision medicine in cardiomyopathy. Stem cell therapy, gene therapy, interfering RNA, and small molecules are actively being evaluated in clinical trials. F1000Research 2017-09-07 /pmc/articles/PMC5590086/ /pubmed/28928965 http://dx.doi.org/10.12688/f1000research.11669.1 Text en Copyright: © 2017 Alvarez P and Tang WW http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Alvarez, Paulino
Tang, WH Wilson
Recent Advances in Understanding and Managing Cardiomyopathy
title Recent Advances in Understanding and Managing Cardiomyopathy
title_full Recent Advances in Understanding and Managing Cardiomyopathy
title_fullStr Recent Advances in Understanding and Managing Cardiomyopathy
title_full_unstemmed Recent Advances in Understanding and Managing Cardiomyopathy
title_short Recent Advances in Understanding and Managing Cardiomyopathy
title_sort recent advances in understanding and managing cardiomyopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5590086/
https://www.ncbi.nlm.nih.gov/pubmed/28928965
http://dx.doi.org/10.12688/f1000research.11669.1
work_keys_str_mv AT alvarezpaulino recentadvancesinunderstandingandmanagingcardiomyopathy
AT tangwhwilson recentadvancesinunderstandingandmanagingcardiomyopathy